Jongkundang has established a new research and development subsidiary, Neurateon, to expand its R&D platform business. The company plans to provide research and development services to domestic and international pharmaceutical and biotech firms, covering areas from new drug research to technology transfer.
On July 8, Jongkundang announced the founding of Neurateon during a ceremony held at the Hyojong Research Institute in Dongbaek, Yongin. The event was attended by over 100 people, including Jongkundang Holdings CEO and Neurateon CEO Won Dong-han.
Neurateon will leverage the research and development capabilities and technologies accumulated at Jongkundang's Hyojong Research Institute to conduct the entire R&D process, including the development of new drug formulations, improved drugs, generics, and over-the-counter (OTC) products, as well as analytical research, formulation research, and drug delivery system (DDS) research.
The company aims to broaden its customer base among domestic and international pharmaceutical and biotech firms by expanding its own product development and technology transfer, positioning itself as a technology-driven R&D platform company.
The name Neurateon combines 'New Era' and 'Technology Innovation,' reflecting the company's goal to usher in a new era in the pharmaceutical industry based on technological competitiveness.
During the launch, Neurateon presented its vision as a 'R&D platform company opening a new era through technological innovation' and outlined its mission to contribute to human health with differentiated technologies and innovative new products. Its core values include Technology, Collaboration, and Innovation.
Won Dong-han, who has been appointed as the CEO of the newly established Neurateon, holds a Ph.D. in pharmacy from Pusan National University and has 23 years of experience in technology research in the pharmaceutical and biotech sectors.
Won stated, 'Neurateon is a technology-based R&D platform company that provides the best services to our customers and partners based on excellent research personnel and expertise. We will differentiate through technology and expand through collaboration to open a new era in the future pharmaceutical industry.'
Since establishing the first central research institute in the domestic pharmaceutical industry in 1972, Jongkundang has continued to invest in raw material and finished product research and development, as well as in training research personnel.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.